Treatment of Angiotensin Peptide (1-7) for COVID-19
- Conditions
- COVID-19
- Registration Number
- NCT04375124
- Brief Summary
Novel Coronavirus is reported to cause COVID-19, recently. It's known that this virus uses ACE (angiotensin converting enzyme) 2 receptors to enter human cells and also blocks the activity of ACE 2. Upon these data the investigators hypothesize that, mortal hyper-inflammation state which is shown in COVID-19 cases, can be a result of angiotensin peptide (1-7) deficiency. Therefore, the aim of this study is to evaluate the possible effect of angiotensin peptide (1-7) supplementation on treatment of COVID-19 cases.
- Detailed Description
Novel Coronavirus is reported to cause COVID-19, recently. It's known that this virus uses ACE (angiotensin converting enzyme) 2 receptors to enter human cells and also blocks the activity of ACE 2. Upon these data the investigators hypothesize that, mortal hyper-inflammation state which is shown in COVID-19 cases, can be a result of angiotensin peptide (1-7) deficiency. Therefore, the aim of this study is to evaluate the possible effect of plasma derived angiotensin peptide (1-7) supplementation on treatment of COVID-19 cases.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 9
- accepted to participate with an informed consent
- proven positive COVID-19
- declined to participate
- genetic/chromosomal abnormalities
- any kind of history of previous adverse events with transfusion
- diagnosis of immune deficiency
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method mortality 4 months mortality rates in two groups will be compared
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Kanuni Sultan Suleyman Training and Research Hospital
🇹🇷Istanbul, Turkey